Company intelligence / Profile preview

Tevva

Tel Aviv-Yafo, Tel Aviv District, Israel

Ownership: Private
Employees: ~37500
Development stage: Other

Overview

Teva has late-stage (Phase 2/3) and marketed products in neuroscience, immunology, CNS, neurodegeneration, and respiratory. Examples: Ajovy is commercially available for migraine, Austedo is leading for chorea in Huntington's and tardive dyskinesia, and several innovative medicines are in pivotal trials (e.g., anti-TL1A antibody for IBD, dual-acting asthma inhaler, long-acting olanzapine).

Therapeutic areas: GastroenterologyNeurologyPulmonology
Modalities: Small moleculeMonoclonal antibodyBiologicAntibodyBiosimilar
Industry: Pharma

Partnerships

BioTime (cell therapy, licensing)Heptares Therapeutics (migraine, small molecules)Kowa (Japan generics JV)Cephalon (acquisition - specialty pharma)

Beyond the preview

Go deeper on Tevva.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tevva.

Explore the full profile